Edward Wood, MD
Ophthalmology · Austin, TXNPI 1487099412
Payments from drug & device makers
Across 405 payments — averaging $1079.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$265K
- Astellas Pharma US Inc$40K
- Boehringer Ingelheim International GmbH$39K
- Baxter Healthcare$36K
- AbbVie$28K
- Apellis Pharmaceuticals, Inc.$8K
- plus $21K from 20 others
Across 13 payments — averaging $244.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3K
What the payments were for
- Consulting fees$69,32163%
- Speaking & faculty fees$29,60027%
- Travel & lodging$3,6473%
- Food & beverage$7,3627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 135 | $264,828 |
| Astellas Pharma US Inc | 36 | $39,532 |
| Boehringer Ingelheim International GmbH | 86 | $39,451 |
| Baxter Healthcare | 20 | $35,930 |
| AbbVie(2 entities) | 27 | $28,361 |
| Apellis Pharmaceuticals, Inc. | 15 | $8,023 |
| Genentech USA, Inc. | 22 | $6,699 |
| Ocular Therapeutix, Inc. | 4 | $5,380 |
| Genentech, Inc. | 4 | $3,639 |
| Johnson & Johnson | 1 | $1,815 |
| Regeneron Healthcare Solutions, Inc. | 29 | $1,337 |
| Harrow Eye, LLC | 1 | $463 |
| Alimera Sciences, Inc. | 3 | $377 |
| Alcon | 3 | $293 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $200 |
| Eyepoint US, Inc. | 3 | $168 |
| Glaukos Corporation | 1 | $166 |
| Rxsight Inc | 1 | $127 |
| Novartis | 1 | $125 |
| Biotissue Holdings Inc. | 1 | $123 |
| ANI Pharmaceuticals, Inc. | 3 | $85 |
| Mallinckrodt Hospital Products Inc. | 3 | $67 |
| Bausch & Lomb Americas Inc. | 1 | $45 |
| Neurotech Pharmaceuticals, Inc. | 1 | $30 |
| Carl Zeiss Meditec USA, Inc. | 1 | $25 |
| Biogen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hillrom - RetinaVue 700 Imager$35,930
- Hillrom - RetinaVue Network$35,930
- Izervay$32,346
- OZURDEX$5,937
- Lucentis$5,898
- VABYSMO$3,851
- Syfovre$2,646
- EYLEA$750
- EYLEA HD$525
- IHEEZO$463
- Iluvien$377
- Clareon$238
- YUTIQ$135
- RXSIGHT CONTACT LENS$127
- RXSIGHT INJECTOR CARTRIDGE$127
- RXSIGHT INJECTOR HANDPIECE$127
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$127
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$127
- SUSVIMO$126
- BEOVU$125
How this compares
$437,306 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 28 | $2,487 |
| Bromfenac Sodium | 18 | $2,270 |
| Prednisolone Acetate | 28 | $1,120 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 97 | $1,021 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $250 |
| Ketorolac Tromethamine | 14 | $195 |
| Latanoprost | 16 | $156 |
| Timolol Maleate | 11 | $87 |
| Brimonidine Tartrate | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Austin
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Shelley GhafooriAustin$2.9M
- Thomas WaltersAustin$2.4M
- Philip StoreyAustin$2.1M
- Saradha ChexalAustin$1.8M
- James DoonerAustin$556K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.